The general manager of Bioiberica highlighted his companys commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients quality of life.
For further information, go to:
http://www.correofarmaceutico.com/2011/10/17/farmacologia/estamos-estupefactos-ante-el-desamparo-en-artrosis
http://www.correofarmaceutico.com/2011/10/17/farmacologia/debemos-aceptar-las-nuevas-reglas-del-juego-y-buscar-oportunidades-entre-ellas
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs
Join Bioiberica at stand F130 in Geneva, 9-11 May to discover the company’s latest science and insights driving innovation in the nutraceuticals market.